Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association最新文献

{"title":"Does Improvement of Glycemic Control Cause Acute Charcot Foot in Patients with Diabetes?","authors":"Ole Lander Svendsen, Rasmus Bo Jansen","doi":"10.1055/a-2498-6826","DOIUrl":"10.1055/a-2498-6826","url":null,"abstract":"<p><p>Recent studies have suggested that improved glycemic control in patients with diabetes may cause acute Charcot foot. To conduct a narrative review of studies investigating whether improved glycemic control in patients with diabetes causes acute Charcot foot.Publications found by searching PubMed, EMBASE, and Cochrane Library as well as reference lists of identified publications were reviewed.Very few publications were found, primarily consisting of case reports and case studies without control groups, documenting instances where cases of acute Charcot foot had been preceded by improved glycemic control. Recent large multicenter randomized placebo-controlled clinical trials of anti-hyperglycemic agents in patients with diabetes, where significant improvement of glycemic control occurred, have not reported incidences of acute Charcot foot.There is so far no solid evidence to suggest that improvement of glycemic control in patients with diabetes causes acute Charcot foot.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"120-132"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Health After Childbirth in Women with Previous Bariatric Surgery: The SPOtMom Pilot Study.","authors":"Ulrike Plank, Kristin Wehrmann, Filiz Oehlhof, Elisabeth Teske, Christine Stier, Florian Seyfried, Wiebke Buchholz, Bodo Warrings, Martin Fassnacht, Andrea Kübler, Ann-Cathrin Koschker","doi":"10.1055/a-2515-3240","DOIUrl":"10.1055/a-2515-3240","url":null,"abstract":"<p><p>Currently, no data are available using standardized instruments for evaluating the postpartum mental health of women with previous bariatric surgery. The aim of this pilot study was to assess postpartum mental health in women following bariatric surgery and to establish appropriate tools for a prospective registry study in the future. In this survey, the mental health of 22 women during the first weeks postpartum was examined (T1) and their status at least 6 months after childbirth was prospectively assessed (T2). Symptoms of depression and anxiety were evaluated with standardized questionnaires and depression was diagnosed with structured diagnostic interviews (SCID-5). At T1, 3/22 women (14%) reported depressive or anxiety symptoms, and in these women, the diagnosis of depression was established. In comparison with T1, at T2, symptomatology for depression or anxiety increased to 32% and 27% of patients, respectively, but only one woman was diagnosed with depression. In comparison to patients without symptoms, patients with signs of depression or anxiety or both had lower total body weight loss and, more often, a personal or family history of depressive disorders. Our pilot study suggests that the rate of postpartum depression in women after BS might be higher than in the general population. High symptom levels of depression and anxiety emphasize the necessity of long-term bariatric follow-up care. Further research is needed to evaluate if prevalence of depression or anxiety disorder or both is higher in this patient group as compared to other patients after bariatric surgery.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"133 3","pages":"112-119"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Oral Glucose Tolerance Test: Changed Results Using Different Drinking Solutions?","authors":"Sabine Schipf, Oliver Kuß, Barbara Thorand, Matthias B Schulze, Matthias Nauck, Claudia Meinke-Franze, Nina Ebert, Sigrid Thierry, Sylvia Gastell, Wolfgang Rathmann","doi":"10.1055/a-2502-8812","DOIUrl":"10.1055/a-2502-8812","url":null,"abstract":"<p><p>The impact of different drinking solutions used for an oral glucose tolerance test (oGTT) on 2-h glucose values and gastrointestinal side effects are not clear. This study compared a commercially produced solution (Accu-Chek Roche solution) and a standardized pharmacy solution (NRF 13.8. oGTT solution) within the German National Cohort (NAKO), including the assessment of gastrointestinal symptoms.The Accu-Chek Roche solution comprises mono- and oligosaccharides with blackcurrant juice for enhanced flavor. The NRF 13.8. oGTT solution contained glucose monohydrates only, with citric acid to maintain the pH for preservation, and did not include flavor enhancers. Within a subgroup of the NAKO participants obtaining a standardized 75g oGTT, 818 participants each received the Accu-Chek Roche solution and the NRF 13.8. oGTT solution matched by study center, sex, age, body mass index, and fasting glucose values. Intra-class correlations for 2-h glucose values were calculated and agreement evaluated with Bland-Altman plots; additionally, coefficients of variation and their difference were estimated for the two solutions.The mean difference of the 2-h glucose concentrations between the Accu-Chek Roche and NRF 13.8. oGTT solution was - 3.4 [95% CI - 6.1; - 0.9] mg/dL. The Bland-Altman plot showed increasing variability of differences with increasing 2-h glucose concentrations without a systematic pattern. The intra-class correlations of 2-h glucose values within matched pairs were 22% [95%CI: 16%; 29%]. The coefficients of variation for 2-h glucose observed with the Accu-Chek Roche and NRF 13.8. oGTT solutions were 25% [24%; 27%] and 25% [23%; 26%], respectively, with a difference of 1% [- 1%; 3%]. Nausea or vomiting were observed in<0.1% of matched participants with no differences between the solutions.The differences in 2-h glucose values and frequency of acute gastrointestinal side effects were not clinically different in participants following the consumption of the Accu-Chek Roche or the NRF 13.8. oGTT solutions.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"133 3","pages":"133-138"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Motor Mononeuropathies in Diabetes Mellitus: A Brief Review.","authors":"Dimitrios Pantazopoulos, Evanthia Gouveri, Dimitrios Papazoglou, Nikolaos Papanas","doi":"10.1055/a-2463-7075","DOIUrl":"10.1055/a-2463-7075","url":null,"abstract":"<p><p>Ocular motor mononeuropathies affect cranial nerves III, IV and VI and are more frequent in diabetes mellitus, with oculomotor nerve involvement being predominant. This narrative brief review discusses the clinical manifestations, diagnosis and management of ocular motor mononeuropathies in subjects with diabetes. Clinical manifestations often include ptosis, diplopia, and periorbital pain. Pupillary sparing is a characteristic of third nerve palsy. Differential diagnosis may be challenging due to overlapping symptoms with nerve palsies of other aetiologies. Treatment includes optimised glycaemic control and management of vascular risk factors. Neuroprotective agents, mainly alpha-lipoic acid and botulinum toxin A have been occasionally used, as well. Spontaneous recovery is seen in many cases.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"73-77"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mechanism and Treatment of Cognitive Dysfunction in Diabetes: A Review.","authors":"Yangbo Hou, Zhen Chen, Jiwei Cheng, Guoyi Li, Lu Yin, Jie Gao","doi":"10.1055/a-2480-7826","DOIUrl":"10.1055/a-2480-7826","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is one of the fastest growing diseases in terms of global incidence and seriously affects cognitive function. The incidence rate of cognitive dysfunction is up to 13% in diabetes patients aged 65-74 years and reaches 24% in those aged >75 years. The mechanisms and treatments of cognitive dysfunction associated with diabetes mellitus are complicated and varied. Previous studies suggest that hyperglycemia mainly contributes to cognitive dysfunction through mechanisms involving inflammation, autophagy, the microbial-gut-brain axis, brain-derived neurotrophic factors, and insulin resistance. Antidiabetic drugs such as metformin, liraglutide, and empagliflozin and other drugs such as fingolimod and melatonin can alleviate diabetes-induced cognitive dysfunction. Self-management, intermittent fasting, and repetitive transverse magnetic stimulation can also ameliorate cognitive impairment. In this review, we discuss the mechanisms linking diabetes mellitus with cognitive dysfunction and propose a potential treatment for cognitive decline associated with diabetes mellitus.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"64-72"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Diagnostic Performances of ATA Guidelines, ACR-TIRADS, and EU-TIRADS and Modified K-TIRADS: A Single Center Study of 4238 Thyroid Nodules.","authors":"Mustafa Özdemir, Gamze Türk, Mustafa Bilgili, Ebru Akay, Ali Koç","doi":"10.1055/a-2498-7952","DOIUrl":"10.1055/a-2498-7952","url":null,"abstract":"<p><p>Several ultrasound-based risk stratification systems (RSSs) have been developed and introduced into clinical practice for managing thyroid nodules. However, there are essential differences among these systems. This study aimed to determine and compare the category-based diagnostic performance of four ultrasound-based risk stratification systems in the detection of thyroid cancer: ACR-TIRADS, ATA, K-TIRADS, and EU-TIRADS.This study included 4238 nodules sampled by fine-needle aspiration biopsy between January 2018 and December 2021. Nodules were classified according to ultrasound imaging features and correlated with biopsy results. The diagnostic success of the risk stratification systems was evaluated and compared.Of the 4238 nodules, 3861 (91.1%) were benign and 376 (8.9%) were malignant. Malignancy was significantly higher in hypoechoic and marked hypoechoic nodules (p=0.001), and solid nodules (p=0.002). For detection of malignancy, areas under the receiving operator characteristics curves were 0.862, 0.850, 0.842, and 0.835 for 2017 ACR-TIRADS, EU-TIRADS, for K-TIRADS, and 2015 American Thyroid Association guidelines, respectively. EU-TIRADS showed the highest sensitivity (91%), whereas ACR-TIRADS had the highest specificity (87%). Compared to other risk stratification systems, ACR-TIRADS resulted in significantly fewer unnecessary biopsies (p=0.009). All RSSs show high diagnostic accuracy and have their own advantages and disadvantages. When selecting an appropriate RSS, the population, the prevalence of the disease, and gender distribution should be considered.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"98-104"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anxiety and Depression in Polycystic Ovary Syndrome: An Analysis Using the Hospital Anxiety and Depression Scale (HADS) in Women from a Low-Income Country.","authors":"Daiane O Simão, Aline Vanessa M P Santos, Vitória S Vieira, Fernando M Reis, Ana Lúcia Cândido, Fabio V Comim, Jéssica A G Tosatti, Karina B Gomes","doi":"10.1055/a-2502-8913","DOIUrl":"10.1055/a-2502-8913","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"105-107"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Low-Density Lipoprotein Cholesterol Apheresis in the Treatment of Familial Hypercholesterolemia: Single Center Experience.","authors":"Hulya Hacisahinogullari, Gamze Bilik Oyman, Ummu Mutlu, Senem Dadin, Gulsah Y Yalin, Ozlem Soyluk, Nurdan Gul, Sevgi Kalayoglu Besisik, Ilhan Satman, Kubilay Karsidag, Ayse Kubat Uzum","doi":"10.1055/a-2460-7066","DOIUrl":"10.1055/a-2460-7066","url":null,"abstract":"<p><strong>Purpose: </strong>  Familial hypercholesterolemia (FH) is a genetic disorder associated with extremely high levels of low-density lipoprotein cholesterol (LDL-C) and increased incidence of cardiovascular disease. We aimed to evaluate the efficacy and long-term outcomes of lipoprotein apheresis (LA) in the treatment of FH.</p><p><strong>Methods: </strong>  Cardiovascular events that occurred before and after LA treatment were evaluated by reviewing previous medical records of patients with FH.</p><p><strong>Results: </strong>  Thirteen patients (female/male: 8/5) were included in this study. The mean Dutch score was 20±4. All patients were treated with a combination of statin and ezetimibe. Before the onset of LA, 8 patients had a history of coronary artery disease, and the median age at onset of cardiovascular disease (CVD) in these patients was 24 years. At the initiation of LA, the median age was 22 years and the mean LDL-C level was 410±130 mg/dL. The mean duration of LA treatment was 13.9±6.9 years. The mean LDL-C levels before and after the latest three LA treatments were 267±63.4 and 71.5±23.4 mg/dL, respectively. The mean reduction in LDL-C levels after LA was 73±8.2%. De novo cardiovascular events occurred in 10 patients during LA treatment; six of these patients had a known history of CVD before LA. Eight of these patients underwent invasive procedures for therapeutic purposes and the total number of procedures was 12.</p><p><strong>Conclusion: </strong>  LA is an effective method of reducing LDL-C levels and an additional treatment option that may slow disease progression in patients with FH who are at high risk of cardiovascular events.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"92-97"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shwachman-Diamond Syndrome and Diabetes: An Update from the Italian Registry and Review of the Literature.","authors":"Antonella Minelli, Emily Pintani, Roberto Valli, Gloria Tridello, Giovanni Porta, Francesca Fioredda, Marco Cipolli, Cesare Danesino","doi":"10.1055/a-2460-6977","DOIUrl":"10.1055/a-2460-6977","url":null,"abstract":"<p><p>The issue of a possible association between Shwachman-Diamond Syndrome and diabetes has been debated for many years. This review updates the Italian Shwachman-Diamond registry, confirming our previous findings that suggest that these patients might be at higher risk of developing diabetes, particularly type 1. These data are of relevance in the clinical follow-up of patients in everyday life, emphasizing the need for early diagnosis and timely intervention.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"78-82"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine Complications in Hepatic Glycogen Storage Diseases: A Long-term Perspective.","authors":"Ja Hye Kim, Yena Lee, Soojin Hwang, Dohyung Kim, Beom Hee Lee, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi","doi":"10.1055/a-2444-4320","DOIUrl":"10.1055/a-2444-4320","url":null,"abstract":"<p><p>Patients with a hepatic type of glycogen storage diseases (GSDs) can manifest endocrine features such as hypoglycemia, dyslipidemia, or osteoporosis. This study aimed to investigate the long-term endocrine consequences in patients with hepatic GSDs.This study included 64 patients from 52 families with hepatic GSDs including GSD type Ia (41 patients from 37 families), Ib (3 unrelated), III (8 from 6 families), IV (1 patient), and IX (11 from 5 families). All patients were genetically confirmed. Clinical and endocrine findings were retrospectively analyzed.The median age at diagnosis and current age were 2.4 years (range, 0.1-42.4 years) and 17.6 years (range, 1.0-47.8 years), respectively. The mean height SDS at diagnosis was -3.5±1.4, and short stature was observed in 35.6% of patients. Patients diagnosed after the age of 3.4 years exhibited a high risk of short stature (OR=36.1; P-value<0.001). Among 33 patients who reached the final height, 23 (69.7%) showed delayed puberty. Hypertriglyceridemia was observed in 46 patients (71.9%), whereas 25 patients (39%) had elevated low-density lipoprotein cholesterol levels during the follow-up period. Among 24 patients who underwent dual-energy X-ray absorptiometry, 22 showed a low bone mineral density Z-score of -3.0±1.3 at the L-spine.This study described the long-term endocrine consequences in patients with hepatic GSDs. Pediatric endocrinologists should be aware of the presenting features and long-term endocrine sequelae of GSDs to provide proper management and decrease its morbidities.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"83-91"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}